|
Identification and characterization of circulating tumor cells in post prostatectomy patients with localized high risk prostate cancer. |
|
|
|
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Genentech; Pfizer |
Speakers' Bureau - Astellas Medivation; Dendreon; Sanofi |
Research Funding - Aragon Pharmaceuticals (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Janssen |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Clovis Oncology; Genentech/Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Research Funding - Genomic Health; Medivation; Myriad Genetics; Takeda |
|
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen; MDxHealth; Myriad Pharmaceuticals |
Research Funding - GenomeDx (Inst); Genomic Health (Inst); Myriad Pharmaceuticals (Inst) |
|
|
Employment - Epic Sciences |
Leadership - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
Patents, Royalties, Other Intellectual Property - Patents Pending |
|
|
No Relationships to Disclose |